BioTime, Inc.

BioTime, Inc. is engaged in the development and commercialization of biopharmaceutical products, focusing on innovative regenerative medicine and advanced stem cell technologies. BioTime, Inc. specializes in regenerative medicine and stem cell therapies.

Founded by a team of experienced professionals, the company operates from its headquarters in Alameda, US. Brian Culley and Rami Skaliter currently serve as CEO. There is no information regarding any recent pivots in strategy or changes in operations. BioTime Inc.

specializes in the development and commercialization of innovative biopharmaceutical products primarily focused on regenerative medicine and stem cell technologies. The company’s core offerings include a range of cellular therapies and related products designed to address various medical needs, such as age-related degenerative diseases and tissue repair. BioTime's flagship products, including its proprietary stem cell lines and advanced therapeutic solutions, cater to a diverse client base comprising research institutions, healthcare providers, and pharmaceutical companies. These products are mainly marketed within the United States and select international markets, notably in Europe and Asia, targeting areas with significant demand for advanced regenerative therapies.

The company aims to enhance patient outcomes through its innovative product pipeline, which emphasizes safety, efficacy, and ease of integration into existing medical frameworks. BioTime Inc. generates revenue through a combination of direct sales of its biopharmaceutical products and collaborations with strategic partners in the healthcare sector. Transactions typically occur via a Business-to-Business (B2B) model, where the company engages with hospitals, research institutions, and pharmaceutical firms looking to incorporate regenerative therapies into their offerings.

Revenue streams are bolstered by licensing agreements and partnerships, which allow clients to access BioTime’s proprietary technologies for their own product development. Specific pricing plans for the company's products and services reflect the value of their innovative technologies, catering to the needs of both large-scale medical institutions and specialized laboratories. The structured sales and partnership agreements enable BioTime to not only capitalize on its advanced product portfolio but also expand its market presence across key geographical regions.